Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early FCR vs Deferred Treatment in Untreated Binet Stage A CLL (CLL7)
NCT00275054Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Oct 2005
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukemia (CLL) (3 cohorts), sponsored by German CLL Study Group. Primary endpoints: Event-free survival and Development of a new prognostic staging system. Started Oct 2005; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00275054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275054.